JP2016521279A - アトラセンタンを使用して脂質プロファイルを改善するための方法 - Google Patents

アトラセンタンを使用して脂質プロファイルを改善するための方法 Download PDF

Info

Publication number
JP2016521279A
JP2016521279A JP2016512012A JP2016512012A JP2016521279A JP 2016521279 A JP2016521279 A JP 2016521279A JP 2016512012 A JP2016512012 A JP 2016512012A JP 2016512012 A JP2016512012 A JP 2016512012A JP 2016521279 A JP2016521279 A JP 2016521279A
Authority
JP
Japan
Prior art keywords
subject
atrasentan
baseline
compared
serum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016512012A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016521279A5 (enExample
Inventor
コール・クレスポ，ブラス
アンドレス，デニス
ブレナン，ピーター・ジェイ
ストルゼンバッチ，ジェームズ・シー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc filed Critical AbbVie Inc
Publication of JP2016521279A publication Critical patent/JP2016521279A/ja
Publication of JP2016521279A5 publication Critical patent/JP2016521279A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016512012A 2013-04-30 2014-04-30 アトラセンタンを使用して脂質プロファイルを改善するための方法 Pending JP2016521279A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361817645P 2013-04-30 2013-04-30
US61/817,645 2013-04-30
US201361824199P 2013-05-16 2013-05-16
US61/824,199 2013-05-16
PCT/US2014/036152 WO2014179453A1 (en) 2013-04-30 2014-04-30 Methods for improving lipid profiles using atrasentan

Publications (2)

Publication Number Publication Date
JP2016521279A true JP2016521279A (ja) 2016-07-21
JP2016521279A5 JP2016521279A5 (enExample) 2017-06-15

Family

ID=50928265

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016512012A Pending JP2016521279A (ja) 2013-04-30 2014-04-30 アトラセンタンを使用して脂質プロファイルを改善するための方法

Country Status (13)

Country Link
US (1) US9855245B2 (enExample)
EP (1) EP2991680A1 (enExample)
JP (1) JP2016521279A (enExample)
KR (1) KR20160003128A (enExample)
CN (1) CN105246512A (enExample)
AU (1) AU2014259961A1 (enExample)
BR (1) BR112015027631A2 (enExample)
CA (1) CA2909871A1 (enExample)
HK (1) HK1221916A1 (enExample)
MX (1) MX2015015036A (enExample)
RU (1) RU2015151175A (enExample)
SG (1) SG11201508960SA (enExample)
WO (1) WO2014179453A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2687027T3 (es) 2010-11-04 2018-10-23 Albireo Ab Inhibidores de ibat para el tratamiento de enfermedades hepáticas
CN106659726A (zh) 2014-06-25 2017-05-10 Ea制药株式会社 固体制剂及其着色防止或着色减少方法
WO2017138878A1 (en) 2016-02-09 2017-08-17 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
CN118852054A (zh) 2019-02-06 2024-10-29 阿尔比里奥公司 苯并硫杂二氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途
CA3161516A1 (en) 2019-12-17 2021-06-24 Philip Thomas FROHLICH Methods of treating iga nephropathy with atrasentan
IL297208A (en) * 2020-04-10 2022-12-01 Chinook Therapeutics Inc Treatment methods for diabetic kidney disease

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2799241A (en) 1949-01-21 1957-07-16 Wisconsin Alumni Res Found Means for applying coatings to tablets or the like
US3173876A (en) 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
NL271831A (enExample) 1960-11-29
US3276586A (en) 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
US3546142A (en) 1967-01-19 1970-12-08 Amicon Corp Polyelectrolyte structures
US3541006A (en) 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US5286497A (en) 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
US5573776A (en) 1992-12-02 1996-11-12 Alza Corporation Oral osmotic device with hydrogel driving member
US5544163A (en) 1994-03-08 1996-08-06 Excel, Inc. Expandable telecommunications system
US7208517B1 (en) 1994-08-19 2007-04-24 Abbott Labortories Endothelin antagonists
US5767144A (en) 1994-08-19 1998-06-16 Abbott Laboratories Endothelin antagonists
US6946481B1 (en) 1994-08-19 2005-09-20 Abbott Laboratories Endothelin antagonists
US7365093B2 (en) 1994-08-19 2008-04-29 Abbott Laboratories Endothelin antagonists
US6162927A (en) 1994-08-19 2000-12-19 Abbott Laboratories Endothelin antagonists
CN1072649C (zh) 1995-09-13 2001-10-10 武田药品工业株式会社 苯并氧杂吖庚因化合物,其生产方法和用途
CL2004000545A1 (es) * 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul
WO2006034094A1 (en) 2004-09-17 2006-03-30 Abbott Laboratories Crystalline form 1 of atrasentan hxdrochloride
EP1802610A1 (en) 2004-09-17 2007-07-04 Abbott Laboratories Crystalline form 2 of atrasentan hydrochloride
US9051301B2 (en) 2004-09-17 2015-06-09 Abbvie Inc. Crystalline form of a drug
US20060135596A1 (en) 2004-09-17 2006-06-22 Zhang Geoff G Amorphous form of a drug
US20070004745A1 (en) * 2005-03-25 2007-01-04 Schering-Plough Corporation Methods of treating benign prostatic hyperplasia or lower urinary tract symptoms by using PDE 5 inhibitors
US20080132710A1 (en) 2006-12-04 2008-06-05 Abbott Laboratories Atrasentan hydrochloride crystalline form 2
EP2545920A1 (en) 2007-08-22 2013-01-16 Abbott GmbH & Co. KG Therapy for complications of diabetes
CN101822837A (zh) * 2010-02-02 2010-09-08 王丽燕 包含艾力沙坦酯盐的药物组合物
CN105324395A (zh) 2013-03-08 2016-02-10 艾伯维公司 治疗急性肾损伤的方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BARTON M, BIOCHIMICA ET BIOPHYSICA ACTA, vol. V1802 N12, JPN5016005266, December 2010 (2010-12-01), pages 1203 - 1213, ISSN: 0003886083 *
BEST P J, ARTERIOSCLEROSIS,THROMBOSIS AND VASCULAR BIOLOGY, vol. V19 N11, JPN5016005264, November 1999 (1999-11-01), pages 2769 - 2775, ISSN: 0003747299 *
BONETTI PIERO, ATHEROSCLEROSIS, vol. V168 N2, JPN5016005263, June 2003 (2003-06-01), pages 367 - 373, ISSN: 0003747298 *
KOHAN DONALD, JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, vol. V22 N4, JPN5016005265, April 2011 (2011-04-01), pages 763 - 772, ISSN: 0003747300 *
RERIANI MARTIN, CIRCULATION, vol. V122 N10, JPN5016005262, September 2010 (2010-09-01), pages 958 - 966, ISSN: 0003886084 *

Also Published As

Publication number Publication date
MX2015015036A (es) 2016-02-09
BR112015027631A2 (pt) 2017-08-22
AU2014259961A1 (en) 2015-11-05
SG11201508960SA (en) 2015-11-27
HK1221916A1 (zh) 2017-06-16
CA2909871A1 (en) 2014-11-06
EP2991680A1 (en) 2016-03-09
CN105246512A (zh) 2016-01-13
US9855245B2 (en) 2018-01-02
US20160074363A1 (en) 2016-03-17
WO2014179453A1 (en) 2014-11-06
KR20160003128A (ko) 2016-01-08
RU2015151175A (ru) 2017-06-07

Similar Documents

Publication Publication Date Title
US9855245B2 (en) Methods for improving lipid profiles using atrasentan
KR101114808B1 (ko) 피복 제제의 제조법
JP5114382B2 (ja) フェノフィブリン酸および／またはそれの塩を含む経口医薬製剤
JP5479318B2 (ja) アログリプチンおよび塩酸メトホルミンを含有する固形製剤
RU2570752C2 (ru) Способы лечения сердечно-сосудистых нарушений
JP5629581B2 (ja) 食物の摂取から独立した消化器疾患の治療方法
RU2359671C2 (ru) Способ получения препарата с покрытием
US20110111022A1 (en) Pharmaceutical formulation
KR20090091085A (ko) 방출성이 제어된 약제학적 제제
JP5044398B2 (ja) 固形製剤
CN1874774B (zh) 包含胰岛素致敏剂、胰岛素促分泌素和聚氧乙烯脱水山梨醇脂肪酸酯的固体制剂
US20060286168A1 (en) Process for producing coated preparation
US20120003307A1 (en) Levetiracetam controlled release composition
US20130078284A1 (en) Pharmaceutical formulations
US20080050444A1 (en) Pharmaceutical compositions of ilaparazole
JP4567340B2 (ja) 被覆製剤の製造方法
EP3025707A1 (en) A multilayer tablet comprising metformin and pioglitazone
JP4478413B2 (ja) 被覆製剤の製造法
JP4361461B2 (ja) 固形製剤
US20100008956A1 (en) Composition and combinations of carboxylic acid losartan in dosage forms
KR20050017090A (ko) 코팅제의 제조 방법
HK1084038A (en) Process for producing coated preparation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170425

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170425

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180227

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181002